A novel antisense oligonucleotide drug for the treatment of chronic hepatitis B: bepirovirsen

doi:10.3969/j.issn.1672-3384.2023.03.003

PDF(432 KB)

Clinical Medication Journal ›› 2023, Vol. 21 ›› Issue (3) : 12-17. DOI: 10.3969/j.issn.1672-3384.2023.03.003

Comment of New Drug

A novel antisense oligonucleotide drug for the treatment of chronic hepatitis B: bepirovirsen

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2023, 21(3): 12-17 https://doi.org/10.3969/j.issn.1672-3384.2023.03.003

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(432 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2023-02-03	2023-03-27
Issue Date
2023-03-27

Please choose a citation manager

Content to export